Ticker >

Hester Biosciences share price

Hester Biosciences Ltd.

NSE: HESTERBIO BSE: 524669 SECTOR: Pharmaceuticals & Drugs  30k   129   12

1660.70
-23.80 (-1.41%)
NSE: Today, 04:05 PM

Price Summary

Today's High

₹ 1680.65

Today's Low

₹ 1649

52 Week High

₹ 1939.95

52 Week Low

₹ 1292.85

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1412.74 Cr.

Enterprise Value

1571.1 Cr.

No. of Shares

0.85 Cr.

P/E

54.35

P/B

4.63

Face Value

₹ 10

Div. Yield

0.48 %

Book Value (TTM)

₹  358.96

CASH

5.96 Cr.

DEBT

164.32 Cr.

Promoter Holding

53.73 %

EPS (TTM)

₹  30.55

Sales Growth

15.8%

ROE

11.53 %

ROCE

11.91%

Profit Growth

-18.16 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Hester Biosciences Ltd.

Xester Toxcinil Inomilk Reproplus CurX Fensafe Allgone Amastic

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year15.8%
3 Year14.45%
5 Year13.51%

Profit Growth

1 Year-18.16%
3 Year1.18%
5 Year1.14%

ROE%

1 Year11.53%
3 Year15.09%
5 Year17.71%

ROCE %

1 Year11.91%
3 Year17.5%
5 Year20.68%

Debt/Equity

0.562

Price to Cash Flow

42.35

Interest Cover Ratio

7.76065876558412

CFO/PAT (5 Yr. Avg.)

0.815610299426016

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 53.73 0
Dec 2023 53.73 0
Sep 2023 53.73 0
Jun 2023 53.73 0
Mar 2023 53.73 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The Company has been maintaining an effective average operating margins of 30.7952206062916% in the last 5 years.
  • The company has a high promoter holding of 53.73%.

 Limitations

  • The company has shown a poor profit growth of 1.17955806865901% for the Past 3 years.
  • The company has shown a poor revenue growth of 14.4506212944936% for the Past 3 years.
  • Company has contingent liabilities of 115.236 Cr.
  • The company is trading at a high EV/EBITDA of 31.4884.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 70.77 60.7 80.35 66.43 65.51
Total Expenditure 51.79 49.78 68.98 54.44 53.94
Operating Profit 18.99 10.92 11.37 11.99 11.57
Other Income 0.96 0.95 0.86 1.22 0.98
Interest 3.14 0.35 0.94 1.48 1.37
Depreciation 2.44 2.62 2.55 2.58 2.57
Exceptional Items 0 0 0 0 0
Profit Before Tax 14.38 8.9 8.73 9.16 8.61
Tax 3.65 2.64 2.26 2.38 2.14
Profit After Tax 10.73 6.26 6.47 6.78 6.48
Adjusted EPS (Rs) 12.61 7.36 7.61 7.97 7.61

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 171.19 169.43 208.48 219.35 254
Total Expenditure 103.42 116.7 136.48 158.78 199.32
Operating Profit 67.76 52.72 71.99 60.57 54.68
Other Income 3.1 2.93 1.65 4.66 5.53
Interest 3.54 5.03 3.95 2.47 6.5
Depreciation 7.57 9.39 9.63 9.5 9.79
Exceptional Items 0 0 -5.28 0 0
Profit Before Tax 59.75 41.23 54.78 53.26 43.92
Tax 15.9 10.01 14.88 13.74 11.58
Net Profit 43.85 31.22 39.9 39.52 32.34
Adjusted EPS (Rs.) 51.55 36.7 46.9 46.45 38.02

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 8.51 8.51 8.51 8.51 8.51
Total Reserves 170.93 194.57 229.07 259.93 283.88
Borrowings 11.37 7.45 2.68 73.25 83.4
Other N/C liabilities 10.14 8.44 7.11 7.92 33.57
Current liabilities 39.3 58.22 34.65 74.84 136.47
Total Liabilities 240.24 277.19 282.02 424.44 545.82
Assets
Net Block 100.81 96.76 86.69 84.31 108.22
Capital WIP 0.42 0.87 3.29 80.22 146.14
Intangible WIP 0 0 0.43 1.69 2.47
Investments 28.22 40.67 43.89 64.69 64.69
Loans & Advances 9.81 11.83 5.32 24.2 6.83
Other N/C Assets 1.58 3.87 2.8 2.86 1.43
Current Assets 99.4 123.18 139.61 166.47 216.05
Total Assets 240.24 277.19 282.02 424.44 545.82
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 59.75 41.23 54.78 53.26 43.92
Adjustment 8.5 12.25 19.61 11.7 14.55
Changes in Assets & Liabilities -16.47 -16.31 -19.8 -32.61 -17.05
Tax Paid -15.58 -11.35 -13.49 -16.44 -8.07
Operating Cash Flow 36.19 25.82 41.1 15.91 33.36
Investing Cash Flow -24.7 -21.33 -3.72 -110.58 -71.96
Financing Cash Flow -20.29 -1.39 -41.33 94.96 41.38
Net Cash Flow -8.8 3.1 -3.95 0.28 2.77

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 53.73 53.73 53.73 53.73 53.73
anup chandravadan kapadia... 2.68 2.68 2.68 2.68 2.68
bela gandhi 4.71 4.71 4.71 4.71 4.71
bhupendra vithaldas gandh... 4.69 4.69 4.69 4.69 4.69
biolink healthcare limite... 2.93 2.93 2.93 2.93 2.93
hester coatings llp 0.75 0.75 0.75 0.75 0.75
hester diagnostics privat... 0.28 0.28 0.28 0.28 0.28
hetal sanjiv gandhi 0.23 0.23 0.23 0.23 0.23
nina rajiv gandhi 8.19 8.19 8.19 8.19 8.19
rajiv dinesh gandhi 10.47 10.47 10.47 10.47 10.47
ravin gandhi 4.74 4.74 4.74 4.74 4.74
sanjiv dinesh gandhi 8.20 8.20 8.20 8.20 8.20
shaila bhupendra gandhi 5.78 5.78 5.78 5.78 5.78
yash rajiv gandhi 0.09 0.09 0.09 0.09 0.09
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 46.27 46.27 46.27 46.27 46.27
darshna dinesh kapadia 1.81 1.81 1.81 1.81 1.81
investor education and pr... 0.93 - - 0.96 0.96
jagrut prataprai gandhi - 1.11 1.11 1.18 1.18
kuntal hasmukhlal shah 3.07 3.07 3.07 3.07 3.07
llp 0.63 0.44 0.20 0.19 0.17
manish jain 2.55 2.55 2.55 2.55 2.88
manish prataprai gandhi - 1.12 1.12 1.18 1.18
vinay shah 1.28 1.28 1.28 1.28 1.28
investor education and pr... - 0.93 0.93 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Hester Biosciences informs about revised certificate9 Apr 2024, 2:18PM Hester Biosciences informs about compliance certificate4 Apr 2024, 1:23PM Hester Biosciences informs about outcome of board meeting2 Feb 2024, 12:33PM Hester Biosciences - Quaterly Results2 Feb 2024, 12:24PM Hester Biosciences - Quaterly Results2 Feb 2024, 12:24PM Hester Biosciences - Quaterly Results2 Feb 2024, 12:24PM Hester Biosciences informs about disclosure30 Jan 2024, 5:11PM Hester Biosciences informs about disclosure30 Jan 2024, 5:07PM Hester Biosciences informs about board meeting 24 Jan 2024, 5:08PM Hester Biosciences informs about certificate8 Jan 2024, 5:26PM Hester Biosciences informs about credit ratings2 Jan 2024, 5:14PM Hester Biosciences informs about trading window closure26 Dec 2023, 3:00PM Hester Biosciences - Quaterly Results7 Nov 2023, 12:25PM Hester Biosciences - Quaterly Results7 Nov 2023, 12:25PM Hester Biosciences - Quaterly Results7 Nov 2023, 12:25PM Hester Biosciences informs about board meeting27 Oct 2023, 5:32PM Hester Biosciences informs about newspaper clipping24 Aug 2023, 11:24AM Hester Biosciences informs about 36th AGM23 Aug 2023, 4:44PM Hester Biosciences informs about AGM and annual report23 Aug 2023, 2:19PM Hester Biosciences informs about newspaper clippings 9 Aug 2023, 10:29AM Hester Biosciences informs about outcome of board meeting8 Aug 2023, 2:49PM Hester Biosciences - Quaterly Results8 Aug 2023, 12:19PM Hester Biosciences - Quaterly Results8 Aug 2023, 12:19PM Hester Biosciences - Quaterly Results8 Aug 2023, 12:19PM Hester Biosciences informs about analyst meet 18 May 2023, 12:33PM Hester Biosciences - Quaterly Results17 May 2023, 1:15PM Hester Biosciences - Quaterly Results17 May 2023, 1:15PM Hester Biosciences - Quaterly Results17 May 2023, 1:15PM Hester Biosciences informs about teleconference call15 May 2023, 11:53AM Hester Biosciences informs about board meeting9 May 2023, 4:55PM Hester Biosciences informs about non-applicability of large corporate entity25 Apr 2023, 5:00PM Hester Biosciences informs about compliance certificate 14 Apr 2023, 9:58AM Hester Biosciences informs about newspaper publication 30 Mar 2023, 10:38AM Hester Biosciences informs about closure of trading window 30 Mar 2023, 10:36AM Hester Biosciences informs about newspaper clipping30 Mar 2023, 10:04AM Hester Biosciences informs about outcome of resolution27 Mar 2023, 3:14PM Hester Biosciences informs about loss of share certificate6 Mar 2023, 1:53PM Hester Biosciences informs about newspaper publication 1 Feb 2023, 10:07AM Hester Biosciences - Quaterly Results31 Jan 2023, 12:39PM Hester Biosciences - Quaterly Results31 Jan 2023, 12:39PM Hester Biosciences - Quaterly Results31 Jan 2023, 12:39PM Hester Biosciences informs about loss of share certificate9 Jan 2023, 12:10PM Hester Biosciences acquires technology from ICAR-NIHSAD to develop H9N2 strain vaccine for poultry28 Dec 2022, 2:28PM Hester Biosciences informs about loss of share certificate19 Dec 2022, 11:36AM Hester Biosciences informs about disclosure of related party transactions16 Nov 2022, 4:31PM Hester Biosciences informs about newspaper publication 7 Nov 2022, 11:19AM Hester Biosciences informs about transcript of earnings conference call7 Nov 2022, 11:16AM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM

Hester Biosciences Stock Price Analysis and Quick Research Report. Is Hester Biosciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Hester Biosciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Hester Biosciences cash from the operating activity was Rs 33.362 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Hester Biosciences has a Debt to Equity ratio of 0.562 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Hester Biosciences , the EPS growth was -18.1566897656306 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Hester Biosciences has OPM of 21.5271653543307 % which is a good sign for profitability.
     
  • ROE: Hester Biosciences have a average ROE of 11.5339077344441 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Hester Biosciences is Rs 1657. One can use valuation calculators of ticker to know if Hester Biosciences share price is undervalued or overvalued.
Last Updated on:
Brief about Hester Biosciences

Hester Biosciences Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Hester Biosciences Limited is a leading biotechnology company specializing in the manufacturing and marketing of vaccines, diagnostics, and related products for animal health. Established in 1987, Hester Biosciences has emerged as a trusted name in the veterinary pharmaceutical industry. With a focus on research and innovation, the company is committed to enhancing animal health and well-being through its high-quality products.

Hester Biosciences Limited :  Share Price

Stay up-to-date with the latest share price of Hester Biosciences Limited by visiting our stock analysis page. Our user-friendly interface allows investors to track the performance of Hester Biosciences in real-time. Analyze historical prices, monitor market trends, and make informed investment decisions using our pre-built screening tools.

Hester Biosciences Limited :  Balance Sheet

Evaluate the financial health of Hester Biosciences Limited by examining its balance sheet. Our website provides access to downloadable annual reports, offering a detailed overview of the company's assets, liabilities, and shareholder equity. Utilize our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, to calculate the fair value of the stock and determine its potential long-term growth.

Hester Biosciences Limited : Annual Report

Gain valuable insights into Hester Biosciences Limited's performance, strategies, and future prospects by accessing the annual reports available for download on our website. Explore the company's achievements, challenges, and financial highlights recorded over the year. Stay informed of key developments and make well-informed decisions based on comprehensive information provided in these reports.

Hester Biosciences Limited :  Dividend

Investors seeking consistent income streams through dividends can keep track of Hester Biosciences Limited's dividend payments. Stay updated with the company's dividend history, payout ratios, and dividend yield on our stock analysis page. Our website provides a convenient platform to monitor dividend trends and assess the company's commitment to rewarding its shareholders.

Hester Biosciences Limited  : Quarterly Results

Monitor Hester Biosciences Limited's financial performance on a quarterly basis by accessing our website's quarterly result section. Download the latest financial statements to analyze revenue, expenses, and profitability indicators. Utilize our premium tools to calculate the fair value of the stock and understand its potential for long-term growth.

Hester Biosciences Limited :  Stock Price Chart

Track the historical movements of Hester Biosciences Limited's stock price through our user-friendly stock price chart. Our website's interactive charts allow investors to analyze price trends, identify patterns, and make informed decisions. Combine technical analysis with fundamental analysis to enhance your understanding of the company's stock performance.

Hester Biosciences Limited :  News

Stay updated with the latest news and developments related to Hester Biosciences Limited on our stock analysis page. Access news articles, press releases, and industry updates to stay informed of key events that may impact the company's performance and stock price. Make informed investment decisions based on current market information.

Hester Biosciences Limited : Concall Transcripts

Access Hester Biosciences Limited's concall transcripts on our website. By reading these transcripts, investors can gain insights into management discussions, future strategies, and industry trends. Stay informed of key announcements and decisions made during the company's earnings calls.

Hester Biosciences Limited : Investor Presentations

Explore Hester Biosciences Limited's investor presentations, available for download on our website. These presentations provide an in-depth understanding of the company's operations, growth strategies, and future plans. Stay updated with the latest developments and assess the company's potential for long-term value creation.

Hester Biosciences Limited : Promoters

Hester Biosciences Limited's promoters play a crucial role in the company's growth and success. Gain insights into the promoters' background, contributions, and strategic involvement in the company's operations. Understand the promoter's vision and commitment to the company's long-term goals.

Hester Biosciences Limited :  Shareholders

Discover the major shareholders of Hester Biosciences Limited on our stock analysis page. Identify institutional investors, mutual funds, and other major stakeholders who hold significant positions in the company. Analyze the shareholder composition to gauge market sentiment and understand the company's appeal to long-term investors.

At our website, we provide a comprehensive platform for long-term stock investors seeking in-depth stock analysis. With our pre-built screening tools and premium features, investors can access a wide range of information including balance sheets, quarterly results, profit and loss statements, annual reports, concall transcripts, investor presentations, credit ratings, and research reports. Empower yourself with the necessary information to make well-informed investment decisions.

Read More
X